ESMO Congress | Conference

Cemiplimab Shows Clinical Benefit in Locally Advanced Basal Cell Carcinoma Following Hedgehog Inhibition

September 18th 2020

The PD-1 antibody cemiplimab established encouraging clinical activity in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression.

Ipatasertib/Chemotherapy Combo Falls Flat in HR+ HER2- Advanced Breast Cancer

September 18th 2020

The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

September 18th 2020

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

Enfortumab Vedotin Sustains OS Benefit in Locally Advanced or Metastatic Urothelial Cancer

September 18th 2020

Enfortumab vedotin-ejfv resulted in a significant improvement in overall survival versus chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who received prior treatment with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.

Futibatinib Demonstrates Promising Responses in FGFR2+ Intrahepatic Cholangiocarcinoma

September 17th 2020

In an interim analysis of a subset of patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements, futibatinib was shown to be efficacious and tolerable.

Experts Consider Long-Term Impact of COVID-19 Pandemic on Oncology Care

September 13th 2020

As the impact of the coronavirus disease 2019 pandemic lingers into the later part of 2020, consideration is needed regarding the lasting effects on patients with cancer who may have experienced delayed care or diagnosis.

Global Study Estimates Widespread Impact of COVID-19 on Cancer Care and Potential Harm to Patients

September 13th 2020

The coronavirus disease 2019 has had a significant impact on cancer care and created widespread challenges for health care systems across the globe.

COVID-19 Crisis Results in Increased Risk of Distress, Burnout Among Oncology Professionals

September 13th 2020

The wellbeing and job performance of oncology professionals has been significantly impacted by the COVID-19 pandemic, and although the extent of this impact is varied between countries, it has been suggested to be related to the crude mortality rate of the virus.

Olaparib/Durvalumab Combo Shows Promising Long-Term Activity in Germline BRCA+ Breast, Ovarian Cancer

October 8th 2019

Updated results from the phase I/II MEDIOLA study strengthen the case for combining olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations. The updated data were featured in two separate presentations at the 2019 ESMO Congress.

Nivolumab/Tivozanib Combo Shows Promise in mRCC

October 8th 2019

Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.

Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC

October 7th 2019

Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.

Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers

October 4th 2019

Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.

Ripretinib Shows Dramatic PFS Improvement for Heavily Pretreated GIST

October 4th 2019

Treatment with the novel KIT and PDGFRA inhibitor ripretinib reduced the risk of progression or death by 85% compared with placebo for heavily pretreated patients with advanced gastrointestinal stromal tumors, according to findings from the phase III INVICTUS trial presented at the ESMO Congress 2019.

Trametinib Emerges as New Standard Option for Recurrent, Low-Grade Ovarian Cancer

October 4th 2019

Treatment with the MEK inhibitor trametinib significantly improves progression-free survival and leads to a strong trend toward improved overall survival in recurrent, low-grade serous ovarian cancer.

Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer

October 3rd 2019

Durvalumab added to etoposide and platinum-based chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer delays development of new lesions and improves patient-reported outcomes compared with etoposide and platinum-based therapy alone.

Entrectinib Delivers Durable Responses in ROS1+, NTRK+ Lung Cancer

October 3rd 2019

Patients with ROS1-positive and NTRK-positive non–small cell lung cancer had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib.

Nivolumab/Ipilimumab Combo Delivers Durable Clinical Activity in Cervical Cancer

October 1st 2019

The combination of nivolumab and ipilimumab appears to have durable clinical activity in patients with recurrent or metastatic cervical cancer.

Cabazitaxel Emerges as Third-Line Standard for Metastatic CRPC

October 1st 2019

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

Nivolumab Improves Survival in Advanced Esophageal Cancer

October 1st 2019

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.

Pembrolizumab Misses PFS Endpoint in Relapsed Malignant Pleural Mesothelioma

September 30th 2019

Pembrolizumab (Keytruda) did not show an improvement in progression-free survival compared with chemotherapy in patients with malignant pleural mesothelioma.